Impact of new screening technologies: should we screen and does phenotype influence this decision?
about
Newborn bloodspot screening policy framework for AustraliaThe Newborn Screening Paradox: Sensitivity vs. Overdiagnosis in VLCAD DeficiencyInternational differences in the evaluation of conditions for newborn bloodspot screening: a review of scientific literature and policy documents.Diagnosing Hepatorenal Tyrosinaemia in Europe: Newborn Mass Screening Versus Selective Screening.Introduction of a Simple Second Tier Screening Test for C5 Isobars in Dried Blood Spots: Reducing the False Positive Rate for Isovaleric Acidaemia in Expanded Newborn Screening.'Personalized medicine': what’s in a name?
P2860
Impact of new screening technologies: should we screen and does phenotype influence this decision?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Impact of new screening techno ...... otype influence this decision?
@en
Impact of new screening techno ...... otype influence this decision?
@nl
type
label
Impact of new screening techno ...... otype influence this decision?
@en
Impact of new screening techno ...... otype influence this decision?
@nl
prefLabel
Impact of new screening techno ...... otype influence this decision?
@en
Impact of new screening techno ...... otype influence this decision?
@nl
P2860
P1476
Impact of new screening techno ...... otype influence this decision?
@en
P2093
James Robert Bonham
P2860
P2888
P304
P356
10.1007/S10545-013-9598-Y
P577
2013-03-19T00:00:00Z
P6179
1044147359